Brief: I-Mab Reports Latest Phase 2 Clinical Data Of Its Differentiated Cd73 Antibody Uliledlimab

NovaBridge Biosciences

27/05/2022 24:51

May 26 (Reuters) - I-Mab  IMAB.O :
    * I-MAB REPORTS LATEST PHASE 2 CLINICAL DATA OF ITS
DIFFERENTIATED
CD73 ANTIBODY ULILEDLIMAB
    * I-MAB - ULILEDLIMAB APPEARS SAFE AND WELL-TOLERATED AS A
MONOTHERAPY AND A COMBINATION THERAPY WITH TORIPALIMAB WITH NO
DOSE LIMITING TOXICITY
    * I-MAB - ENCOURAGING EFFICACY SIGNALS WERE OBSERVED IN A
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENT COHORT
    * I-MAB - RESULTS INDICATE CD73 EXPRESSION CORRELATES WITH
CLINICAL RESPONSE AS A POTENTIAL PREDICTIVE BIOMARKER
    * I-MAB - COMPANY AIMS TO INITIATE PHASE 3 STUDY IN NSCLC IN
2023

Source text for Eikon:  ID:nPn64kp7ma 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))